Seattle Children’s opens first pediatric CAR T-Cell trial targeting CD22 and CD19 proteins – EurekAlert (press release)
EurekAlert (press release) |
Seattle Children's opens first pediatric CAR T-Cell trial targeting CD22 and CD19 proteins
EurekAlert (press release) Seattle Children's has opened the first chimeric antigen receptor (CAR) T-cell immunotherapy trial in the U.S. for children and young adults with relapsed or refractory CD19- and CD22-positive acute lymphoblastic leukemia (ALL) that will simultaneously … New immunotherapy study aims to prevent children with leukemia from relapsing |
